Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

Inclusion Criteria: * A male or female infant between 6 and 8 weeks of age at the time of the first vaccination. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * Written informed consent obtained from the parents or guardians of the subject. * Born after a normal gestation period (between 36 and 42 weeks). Exclusion Criteria: * Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine. * Administration of chronic immunosuppressants or other immune-modifying drugs since birth or planned administration during the study. * Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after. * Previous vaccination against diphtheria, tetanus, pertussis, polio or Haemophilus influenzae type b. * History of, or intercurrent, diphtheria, tetanus, pertussis, hepatitis B, polio and/or Haemophilus influenzae type b. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection. * Major congenital defects * Serious chronic illness * History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. * Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. * Acute disease at the time of enrollment.